CN115850686A - Novel deuterated PEG lipid compound, preparation method, composition and application thereof - Google Patents
Novel deuterated PEG lipid compound, preparation method, composition and application thereof Download PDFInfo
- Publication number
- CN115850686A CN115850686A CN202111133137.0A CN202111133137A CN115850686A CN 115850686 A CN115850686 A CN 115850686A CN 202111133137 A CN202111133137 A CN 202111133137A CN 115850686 A CN115850686 A CN 115850686A
- Authority
- CN
- China
- Prior art keywords
- ext
- aext
- deuterated
- composition
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- -1 lipid compound Chemical class 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 150000002632 lipids Chemical class 0.000 claims abstract description 58
- 150000001875 compounds Chemical class 0.000 claims abstract description 45
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 14
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 14
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 32
- 229920001223 polyethylene glycol Polymers 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000002202 Polyethylene glycol Substances 0.000 claims description 19
- 108020004999 messenger RNA Proteins 0.000 claims description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 230000000069 prophylactic effect Effects 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 230000007935 neutral effect Effects 0.000 claims description 11
- 150000003431 steroids Chemical class 0.000 claims description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 9
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- 229910052805 deuterium Inorganic materials 0.000 claims description 7
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 6
- 125000002091 cationic group Chemical group 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 5
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 claims description 5
- HSBMBJDVXFRTTD-UHFFFAOYSA-N C(CCCCC)C(C(=O)OCCCCCCOC(C(CCCCCCCC)CCCCCC)=O)CCCCCCCC Chemical compound C(CCCCC)C(C(=O)OCCCCCCOC(C(CCCCCCCC)CCCCCC)=O)CCCCCCCC HSBMBJDVXFRTTD-UHFFFAOYSA-N 0.000 claims description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 5
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- 239000004593 Epoxy Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 claims description 2
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 claims description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 2
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 claims description 2
- WTJKGGKOPKCXLL-VYOBOKEXSA-N 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC WTJKGGKOPKCXLL-VYOBOKEXSA-N 0.000 claims description 2
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 claims description 2
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 claims description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims description 2
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 claims description 2
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 claims description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- XYNPYHXGMWJBLV-VXPJTDKGSA-N Tomatidine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@@]11CC[C@H](C)CN1 XYNPYHXGMWJBLV-VXPJTDKGSA-N 0.000 claims description 2
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 claims description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 229940087168 alpha tocopherol Drugs 0.000 claims description 2
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 claims description 2
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 claims description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 2
- 235000004420 brassicasterol Nutrition 0.000 claims description 2
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 claims description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims description 2
- 235000000431 campesterol Nutrition 0.000 claims description 2
- QYIXCDOBOSTCEI-NWKZBHTNSA-N coprostanol Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-NWKZBHTNSA-N 0.000 claims description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims description 2
- 229960004956 glycerylphosphorylcholine Drugs 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- QAZHYRJYZIMJJI-UHFFFAOYSA-N n-ethylpiperazin-1-amine Chemical compound CCNN1CCNCC1 QAZHYRJYZIMJJI-UHFFFAOYSA-N 0.000 claims description 2
- PWRIIDWSQYQFQD-UHFFFAOYSA-N sisunine Natural products CC1CCC2(NC1)OC3CC4C5CCC6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OC(CO)C(O)C(O)C9OC%10OC(CO)C(O)C(O)C%10O)C8O)C(O)C7O PWRIIDWSQYQFQD-UHFFFAOYSA-N 0.000 claims description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 2
- 235000015500 sitosterol Nutrition 0.000 claims description 2
- 229950005143 sitosterol Drugs 0.000 claims description 2
- 239000004055 small Interfering RNA Substances 0.000 claims description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 2
- 235000016831 stigmasterol Nutrition 0.000 claims description 2
- 229940032091 stigmasterol Drugs 0.000 claims description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 229960000984 tocofersolan Drugs 0.000 claims description 2
- XYNPYHXGMWJBLV-OFMODGJOSA-N tomatidine Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@@H](C)[C@]6(O[C@H]5C4)NC[C@@H](C)CC6)CC3)CC2)CC1 XYNPYHXGMWJBLV-OFMODGJOSA-N 0.000 claims description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 2
- 229940096998 ursolic acid Drugs 0.000 claims description 2
- 239000002076 α-tocopherol Substances 0.000 claims description 2
- 235000004835 α-tocopherol Nutrition 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 5
- 230000003834 intracellular effect Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 171
- 238000005160 1H NMR spectroscopy Methods 0.000 description 88
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 88
- 230000015572 biosynthetic process Effects 0.000 description 79
- 238000003786 synthesis reaction Methods 0.000 description 78
- 239000002105 nanoparticle Substances 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Substances CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- VTRBOZNMGVDGHY-UHFFFAOYSA-N 6-(4-methylanilino)naphthalene-2-sulfonic acid Chemical compound C1=CC(C)=CC=C1NC1=CC=C(C=C(C=C2)S(O)(=O)=O)C2=C1 VTRBOZNMGVDGHY-UHFFFAOYSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000254064 Photinus pyralis Species 0.000 description 1
- 229930185560 Pseudouridine Natural products 0.000 description 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 1
- MXZNUGFCDVAXLG-CHWSQXEVSA-N [(2S)-1-[(2R)-3-methyl-2-(pyridine-4-carbonylamino)butanoyl]pyrrolidin-2-yl]boronic acid Chemical compound CC(C)[C@@H](NC(=O)c1ccncc1)C(=O)N1CCC[C@@H]1B(O)O MXZNUGFCDVAXLG-CHWSQXEVSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- MRMOMIYVTPUCMS-UHFFFAOYSA-N acetic acid;pyrrolidine-2,5-dione Chemical compound CC(O)=O.O=C1CCC(=O)N1 MRMOMIYVTPUCMS-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical group OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- HFCSXCKLARAMIQ-UHFFFAOYSA-L disodium;sulfate;hydrate Chemical compound O.[Na+].[Na+].[O-]S([O-])(=O)=O HFCSXCKLARAMIQ-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- VMFMUJZRXZXYAH-UHFFFAOYSA-N n-[5-[[5-chloro-4-[2-[2-(dimethylamino)-2-oxoacetyl]anilino]pyrimidin-2-yl]amino]-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl]prop-2-enamide Chemical compound C=CC(=O)NC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)C(=O)C(=O)N(C)C)C(Cl)=CN=2)C(OC)=CC=1N1CCN(C)CC1 VMFMUJZRXZXYAH-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000008243 triphasic system Substances 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Polymers & Plastics (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a novel deuterated PEG lipid compound, a preparation method, a composition and application thereof, and particularly discloses a novel deuterated lipid compound shown as a formula A and a formula B, or pharmaceutically acceptable salt or isomer thereof. Also discloses a preparation method, a composition and application of the PEG lipid compound. The compounds are used as functional PEG lipids, pharmaceutical compositions suitable for nucleic acid delivery, can achieve superior stability, water solubility, and intracellular delivery efficiency of the drug, wherein A and formula B are as follows.
Description
Technical Field
The present invention provides novel deuterated polymer-conjugated lipids that can be used in combination with other lipid components (e.g., neutral lipids, steroids, and cationic lipids) to form a nucleic acid mRNA lipid nanoparticle composition for delivering one or more therapeutic and/or prophylactic agents to mammalian cells or organs and/or for producing polypeptides in mammalian cells or organs. In addition to the novel deuterated lipids, the lipid nanoparticle compositions of the present invention can include one or more deuterated polymer-conjugated lipids, neutral lipids including polyunsaturated lipids, cationic lipids, steroids, and/or therapeutic and/or prophylactic agents in specific ratios.
Background
Effective targeted delivery of biologically active substances such as small molecule drugs, proteins and nucleic acids presents a long-standing medical challenge. In particular, delivery of nucleic acids to cells is made difficult by the relative instability and low cell permeability of these species. Accordingly, there is a need to develop methods and compositions that facilitate the delivery of therapeutic and/or prophylactic agents, such as nucleic acids, to cells.
Studies have shown that bioactive substances such as small molecule drugs, proteins and nucleic acids can be efficiently delivered to cells and/or intracellular compartments using lipid-containing nanoparticle compositions, liposomes and liposome complexes as delivery vehicles. These compositions generally comprise one or more polymer-conjugated lipids, neutral lipids (e.g., phospholipids), structural lipids (e.g., steroids), and/or cation-containing lipids, including polyunsaturated lipids.
However, the use of oligonucleotides in a therapeutic setting is currently facing two problems. First, free RNA is susceptible to nuclease digestion in plasma. Second, the ability of free RNA to enter intracellular compartments where relevant translation mechanisms exist is limited. Lipid nanoparticles formed from pegylated deuterated lipids with other lipid components (such as neutral lipids, cholesterol, cationic lipids, and oligonucleotides) have been used to prevent degradation of RNA in plasma and promote cellular uptake of oligonucleotides, while deuterated polymer-conjugated lipids have not been reported.
Therefore, there remains a need for improved deuterated pegylated lipids and lipid nanoparticles for delivering oligonucleotides. The improved lipid compounds and lipid nanoparticles would improve physicochemical properties, provide optimized drug delivery, protect nucleic acids from degradation and clearance in serum, be suitable for systemic or local delivery, and provide intracellular delivery of nucleic acids. In addition, these preferred lipid-nucleic acid particles should be well-tolerated and provide a sufficient therapeutic index such that patient treatment at an effective dose of the nucleic acid does not result in unacceptable toxicity and/or risk to the patient. The present invention provides these and related advantages.
Disclosure of Invention
The invention provides the following novel polyethylene glycol lipid compounds (as shown in the following formula A and formula B) and preparation methods, compositions and applications of the compounds.
1. The invention relates to a deuterated polyethylene glycol lipid compound (A):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
r1, R2, R3 are each independently a combination of DDD, DDH, DHH, HHH, DD, DH, HH, D, H;
r1, R2, and R3 are all independent, and when R1 and R2 are both "HHH", R3 cannot be "HH", and when R3 is a combination of "HH", one of R1 and R2 cannot be a combination of "HHH";
r1, R2, are each independently a "DDD" combination, R3 is independently a "DD" combination;
the average value of n is 40 to 50, preferably 45.
2. The invention relates to a deuterated polyethylene glycol lipid compound (B):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
r1, R2, R3, R4, R5 are each independently a combination of DDD, DDH, DHH, HHH, DD, DH, HH, D, H;
r1, R2, R3, R4 and R5 are all independent, when R1 and R2 are both the combination of 'HHH' and R4 is the combination of 'H', R3 and R5 can not be simultaneously 'HH'; when R3 and R5 are both the combination of 'HH' and R4 is the combination of 'H', R1 and R2 can not be the combination of 'HHH' at the same time; when R1, R2 are both "HHH" combinations, and R3, R5 are both "HH" combinations, R4 cannot be "H" combinations;
r1, R2, R3, R4, R5 are each independently a combination of "DDD", "DD", "D";
the average value of n is 40 to 50, preferably 45.
In various embodiments, the compound has one of the structures shown in table 1 below
Table 1 representative novel PEG lipid compounds
In some embodiments, compositions are provided comprising any one or more of the deuterated compounds of structural formulae (a) and (B) and a therapeutic and/or prophylactic agent.
In some embodiments, compositions are provided comprising any one or more of the compounds of structures (a) and (B) and a therapeutic and/or prophylactic agent. In some embodiments, the composition comprises any of the compounds of structures (a) and (B) and a therapeutic and/or prophylactic agent and one or more excipients selected from the group consisting of neutral lipids, steroids, and cationic lipids. Other pharmaceutically acceptable excipients and/or carriers are also included in various embodiments of the compositions.
In some embodiments, the neutral lipid is selected from 1, 2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1, 2-dimyristyl-sn-glycero-phosphocholine (DMPC), 1, 2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1, 2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), sphingomyelin (SM), and mixtures thereof. In some embodiments, it is preferred that the neutral lipid is 1, 2-distearoyl-sn-glycero-3-phosphocholine (DSPC).
In some embodiments, the steroid is selected from the group consisting of cholesterol, coprosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof. In some embodiments, it is preferred that the steroid is cholesterol. In some embodiments, the cationic lipid is selected from 4- (N, N-dimethylamino) butanol (6z, 9z,28z, 31z) -heptatriacontan-6, 9,28, 31-tetraen-19-yl ester (DLin-MC 3-DMA), heptadecan-9-yl-8- ((2-hydroxyethyl) (6-oxo-6- ((decyloxy) hexyl) amino) caprylate (SM-102), ((4-hydroxybutyl) aza-ethyl) bis (hexane-6, 1-diyl) bis (2-hexyldecanoate) (ALC-0315), 4- (N-2- (N, N-bis (2-hydroxydodecyl) ethylamino) -1-N (2-ethylamino- (2- (N, N-bis (2-hydroxydodecyl)) -2 hydroxydodecyl) ethylamino piperazine (C12-200), novel lipid compounds of the pyrrolidine class.
In some embodiments, the cationic lipid is preferably selected from the group consisting of ((4-hydroxybutyl) aza-ethyl) bis (hexane-6, 1-diyl) bis (2-hexyldecanoate) (ALC-0315) deuterated analogs, deuterated analogs of heptadecan-9-yl-8- ((2-hydroxyethyl) (6-oxo-6- ((decyloxy) hexyl) amino) octanoate (SM-102).
The cationic lipid in the composition of the invention has the following structure (formula I):
wherein:
l1 is selected from the following structures: -C-, -O (C = O) -, - (C = O) O-, -C (= O) -, -O-, -S (O) X-, -S-, -C (= O) S-, -SC (= O) -, -N-C (= O) -, -C (= O) -N-, L2 is selected from the following structures: -C-, - (C = O) O-, -C (= O) -, -S (O) X-, -C (= O) S-, -C (= O) -N-;
r1 and R2 are each independently C6-C24 alkyl or C6-C24 alkenyl, said hydrocarbyl chains optionally being linked by one or more ester or ether linkages; r3 and R4 are each independently C1-C12 alkyl or C1-C12 alkenyl, or R3 and R4 combine with each other to form a 4-to 10-membered heterocyclic ring, the heteroatoms including one or more of N, O, S, the heterocyclic ring being optionally substituted with 1-6 heteroatoms;
x is C, N, O, S, -S-S-; m is C1-C12 alkyl or C1-C12 alkenyl; x is 0, 1 or 2.
The cationic lipid compounds in the composition according to the invention are preferably all cationic lipid compounds disclosed in the following patent application nos.: CN2021109304214, CN2021109693918, CN2021109698790, CN2021109700095, CN202110970112X, CN2021109787347, CN2021110306263, CN2021110307694, CN2021110439195, CN2021110310644, CN2021110311986, CN2021111108325, CN2021111057272.
In some embodiments, the composition ratio is in the following range: about 1-10mol% of said compound, about 0-30 mol% of neutral lipids, about 10-55 mol% of steroids and about 30-60mol% of cationic lipids.
In some embodiments of the foregoing composition, the therapeutic and/or prophylactic agent comprises a nucleic acid. Wherein the nucleic acid is RNA selected from the group consisting of: siRNA, aiRNA, miRNA, dsRNA, shRNA, mRNA and mixtures thereof. In some embodiments, the RNA is selected from mRNA.
In other various embodiments, the invention relates to a method of administering a therapeutic and/or prophylactic agent to a subject in need thereof, the method comprising preparing or providing any of the above compositions and administering the composition to the subject.
For administration purposes, the compounds of the invention (typically in the form of lipid nanoparticles in combination with a therapeutic and/or prophylactic agent) can be administered as a drug substance or can be formulated as a pharmaceutical composition. The pharmaceutical compositions of the present invention comprise compounds of structures (a) and (B) and one or more pharmaceutically acceptable carriers, diluents, or excipients. The compounds of structures (a) and (B) are effective to form lipid nanoparticles and deliver therapeutic and/or prophylactic agents. Appropriate concentrations and dosages can be readily determined by those skilled in the art.
Administration of the compositions of the present invention may be by any acceptable manner of administration of the agents for similar utility. The pharmaceutical composition of the present invention may be formulated into preparations in solid, semi-solid, liquid or gaseous form, such as tablets, capsules, powders, granules, ointments, solutions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols. Typical routes of administration of such pharmaceutical compositions include, but are not limited to, oral, topical, transdermal, inhalation, parenteral, sublingual, buccal, rectal, vaginal and intranasal routes. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intradermal, intrasternal injection or infusion techniques. The pharmaceutical compositions of the present invention are formulated so as to allow the active ingredient contained therein to be bioavailable upon administration of the composition to a subject. The composition to be administered to a subject or patient is in the form of one or more dosage units, wherein a tablet may be a single dosage unit, while a container of a compound of the invention in aerosol form may contain a plurality of dosage units. Current methods of preparing these dosage forms are known or will be apparent to those skilled in the art. In any event, the composition to be administered will contain a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, in order to treat the relevant disease or condition in accordance with the teachings of the present invention.
The pharmaceutical compositions of the present invention may be in solid or liquid form. In one aspect, the carrier is a microparticle such that the composition is in the form of a tablet or powder. The carrier may be a liquid, in which case the composition is an oral syrup or an injectable liquid or aerosol, which is suitable for inhalation administration.
When intended for oral administration, the pharmaceutical composition is preferably in solid or liquid form, wherein forms considered herein to be solid or liquid include semi-solid, semi-liquid, suspension, and gel forms.
As solid compositions for oral administration, the pharmaceutical compositions may be formulated into the form of powders, granules, compressed tablets, pills, capsules, chewing gums, wafers, and the like. Such solid compositions will generally contain one or more inert diluents or edible carriers. Additionally, one or more of a binder, such as gelatin, cellulose, and the like; excipients, such as lactose and the like; disintegrating agents such as alginic acid and the like; lubricants, such as magnesium stearate and the like; glidants such as silicone gel and the like; sweetening agents, such as sucrose or saccharin; flavoring agents such as herba Menthae; and a colorant.
When the pharmaceutical composition is in the form of a capsule, it may contain a liquid carrier other than the above-mentioned types of materials, such as polyethylene glycol or an oil.
The pharmaceutical composition may be in the form of a liquid, such as a syrup, solution, emulsion or suspension. As two examples, the liquid may be for oral administration or for injection delivery. When intended for oral administration, the compositions of the present invention contain, in addition to the compounds of the present invention, one or more of sweetening agents, preserving agents, coloring/colouring agents and taste enhancers. In compositions for administration by injection, one or more of surfactants, preservatives, wetting agents, dispersing agents, suspending agents, buffers, stabilizing agents and isotonic agents may be included.
The liquid pharmaceutical compositions of the present invention, whether in solution, suspension or other similar form, may include one or more of the following adjuvants, such as sterile diluents, e.g., water for injection, saline solution, preferably normal saline, ringer's solution, isotonic sodium chloride; non-volatile oils such as synthetic monoglycerides or diglycerides which may be used as a solvent or suspending medium, polyethylene glycols, glycerol, propylene glycol or other solvents; antibacterial agents such as methyl paraben vinegar; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers such as acetates, squarates or phosphates; and agents for regulating tonicity, such as sodium chloride or dextrose; agents used as cryoprotectants, such as sucrose or trehalose. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Physiological saline is a preferred adjuvant. Injectable pharmaceutical compositions are preferably sterile.
The pharmaceutical compositions of the present invention may be comprised of dosage units that can be administered as an aerosol. The term aerosol is used to denote a variety of systems ranging from systems of colloidal nature to systems consisting of pressurized packaging. Delivery may be by liquefied or compressed gas, or by a suitable pump system for dispensing the active ingredient. Aerosols of the compounds of the invention may be delivered as a single phase, biphasic system, or triphasic system for delivery of the active ingredient. The delivery of the aerosol includes the necessary containers, activators, valves, sub-containers, etc., which together may form a kit. One skilled in the art can determine the preferred aerosol without undue experimentation.
The pharmaceutical compositions of the present invention may be prepared by methods well known in the pharmaceutical arts. Pharmaceutical compositions intended for administration by injection may be prepared by combining the lipid nanoparticles of the present invention in solution with sterile distilled water or other carrier. Surfactants may be added to facilitate the formation of a homogeneous solution or suspension. Surfactants are compounds that interact non-covalently with the compounds of the present invention in order to facilitate dissolution or uniform suspension of the compounds in an aqueous delivery system.
The compositions of the present invention, or pharmaceutically acceptable salts thereof, are administered in therapeutically effective amounts, which will vary depending on a variety of factors, including the activity of the particular therapeutic agent employed; metabolic stability and length of action of the therapeutic agent; the age, weight, general health, sex, and diet of the subject; the mode and time of administration; the rate of excretion; a drug combination; severity of the particular case, etc.
The compositions of the present invention may also be administered simultaneously with, before or after the administration of one or more other therapeutic agents. Such combination therapies include the administration of a single pharmaceutical dosage formulation of a composition of the present invention and one or more additional active agents, as well as the administration of a composition of the present invention and each active agent in its own separate pharmaceutical dosage formulation. For example, the compositions of the invention and other active agents can be administered to a subject together in a single oral dosage composition (e.g., a tablet or capsule), or each agent can be administered in different oral dosage formulations. When different dosage formulations are employed, the compound of the invention and one or more additional active agents may be administered at substantially the same time, or sequentially at staggered times; it is to be understood that combination therapy encompasses all such regimens.
The structure modification and design of the deuterated PEGylated deuterated lipidosome compound realize more advantageous physicochemical properties including more proper pKa and better chemical stability, and the deuterated PEGylated deuterated lipidosome compound is used for an mRNA nanoliposome composition, can realize more effective combination and delivery of ionic nucleic acid drugs, has more stable chemical structure, is convenient to synthesize and is beneficial to being developed into pharmaceutic adjuvant.
Methods for preparing the above compounds and compositions are described below, and/or are known in the art.
One skilled in the art will recognize that in the processes described herein, functional groups of starting materials and intermediates include epoxy, hydroxyl, amino, and amide. The method can be used for substitution, reduction, condensation and the like, is suitable for the method for preparing amine by amide reduction, and mainly comprises a metal hydride reduction method, a borane tetrahydrofuran complex reduction method, a catalytic hydrogenation reduction method, a sodium borohydride-Lewis acid system reduction method and the like. The amide production method mainly includes an ammonia ester exchange method, an aliphatic amine and ester exchange method, an acid anhydride-based raw material method, an acid halide-based raw material method, an organic phosphorus-based condensing agent method, an onium salt-based condensing agent method, and the like. The epoxy ring opening is primarily catalyzed by acid and alkaline, and the method can be selected based on the nature of the substrate, and standard techniques are known to those skilled in the art and described herein.
One skilled in the art will also recognize that while such reduced and condensed derivatives of the compounds of the present invention may not be pharmaceutically active thereby, they may be administered to a mammal and thereafter metabolized in vivo to form the compounds of the present invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". Prodrugs of the compounds of the invention are therefore included within the scope of the invention.
Furthermore, all compounds of the invention in free base or free acid form can be converted into their pharmaceutically acceptable salts by treatment with a suitable inorganic or organic base or acid according to methods known to those skilled in the art. Salts of the compounds of the invention may be formed by conversion to the free base or acid thereof by standard techniques.
The following examples are provided for the purpose of illustration and not limitation.
The following examples, unless otherwise indicated, all solvents and reagents used were commercially available and used as received.
The procedure described below can be used for the synthesis of compounds a and B.
The following abbreviations are used herein:
DCM: methylene dichloride
THF: tetrahydrofuran (THF)
MeOH: methanol
HBTU:2- (benzotriazole) -N, N, N, N-tetramethyluronium hexafluorophosphate
DIEA: diisopropylethylamine
DMF: n, N-dimethylformamide
LiAlH 4 : lithium aluminum tetrahydride
NaOH: sodium hydroxide
PEG: polyethylene glycol
DMSO-d6: deuterated dimethyl sulfoxide
EA: acetic acid ethyl ester
PE: petroleum ether (60-90)
EDCI: 1-Ethyl- (3-dimethylaminopropyl) carbodiimides hydrochloride
DMAP: n, N-lutidine.
Detailed Description
Example 1
Representative routes
A compound A: synthesis of N, N-bis (14, 14-D3-tetradecyl) -2, 2-2D-2-methylpolyethylene glycol acetamide
1) Ext> Synthesisext> ofext> 14,14,14ext> -ext> Dext> 3ext> -ext> tetradecanamideext> (ext> dPEGext> -ext> Aext> -ext> 3ext>)ext>
The molecular formula is as follows: c 14 H 26 D 3 NO
Molecular weight 230.40
Ext> oxalylext> chlorideext> (ext> 38.85mmoext> 1ext>,ext> 4.93gext>)ext> wasext> addedext> toext> aext> solutionext> ofext> 14,14ext>,ext> 14ext> -ext> Dext> 3ext> -ext> tetradecanoicext> acidext> (ext> dPEGext> -ext> Aext> -ext> 1ext>)ext> (ext> 6ext> gext>,ext> 25.9ext> mmoext> 1ext>)ext> inext> tolueneext> (ext> 50ext> mLext>)ext> atext> roomext> temperatureext>.ext> After heating the resulting mixture at 70 ℃ for 2h, the mixture was concentrated. The residue was dissolved in toluene and concentrated again. The residual oil was added to a concentrated ammonia solution (20 m) by syringe at 10 ℃. The reaction mixture was filtered and washed with water. The white solid was dried in vacuo. Ext> theext> desiredext> productext>,ext> 14ext> -ext> Dext> 3ext> -ext> tetradecanamideext> (ext> dPEGext> -ext> Aext> -ext> 3ext>)ext>,ext> wasext> obtainedext> asext> aext> whiteext> solidext> (ext> 3.58gext>,ext> 60ext>%ext>)ext>.ext>
APCI-MS:m/z 231[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 6.8(s,2H),2.28(t,2H,J=7.2Hz),1.80(m,2H),1.35(m, 2H),1.24(m,18H)。
2) Ext> Synthesisext> ofext> 14,14,14ext> -ext> Dext> 3ext> -ext> tetradecylamineext> (ext> dPEGext> -ext> Aext> -ext> 4ext>)ext>
The molecular formula is as follows: c 14 H 28 D 3 N
Molecular weight 216.40
To a suspension of 14,14, 14-D3-tetradecanamide (3.58g, 15.54mm01) in THF (70 mL) was added lithium aluminum hydride (1.14g, 30mmol) portionwise at room temperature over a period of 30 min. The mixture was then slowly heated to reflux (65 ℃ oil bath) overnight. The mixture was cooled to 5 ℃ and sodium sulfate hydrate was added. The mixture was stirred for 2h, filtered through a celite layer, and washed with 15% meoh in DCM (200 m). The filtrate and washings were combined and concentrated. The residual solid was dried under vacuum 29197. Ext> 14,14ext>,ext> 14ext> -ext> Dext> 3ext> -ext> tetradecylamineext> (ext> dPEGext> -ext> Aext> -ext> 4ext>)ext> wasext> obtainedext> asext> aext> whiteext> solidext> (ext> 2.86ext>,ext> 85.1ext>%ext>)ext>.ext>
APCI-MS:m/z 217[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 3.7(s,2H),2.72(m,2H),1.65(m,2H),1.35(m, 2H),1.24(m,20H)。
3) Ext> Synthesisext> ofext> 14,14,14ext> -ext> Dext> 3ext> -ext> tetradecylext> -ext> 14,14,14ext> -ext> Dext> 3ext> -ext> tetradecylamideext> (ext> dPEGext> -ext> Aext> -ext> 5ext>)ext>
The molecular formula is as follows: c 29 H 53 D 6 NO
Molecular weight 443.82
To a solution of 14,14, 14-D3-myristic acid (1 g,4.3 mmol) in benzene (10 mL) and DMF (1 drop) was added oxalyl chloride (0.82g, 6.45mmol) at room temperature, and the mixture was stirred at room temperature for 3h. After concentration at 60 ℃ to remove toluene, the residual oil was dissolved in 5mL of benzene and cooled to 10 ℃ it was added to a solution of 14, 14-D3-tetradecylamine (0.97g, 4.5 mol) and triethylamine (0.65 g,6.45 mmol) in benzene (5 mL). After the addition was complete, the reaction was stirred at room temperature overnight. After completion of the reaction, water was added, diluted with water, and adjusted to pH5-6 with 1.7M HCl, and a solid was precipitated, stirred at room temperature for 5 hours, filtered, and washed with water. An off-white wet product is obtained, the wet product is heated to 58 ℃ by 5ml of methanol to be dissolved, the temperature is reduced to room temperature, the stirring is carried out for 8 hours, the filtration is carried out, 1ml of methanol is used for leaching, and the obtained solid is dried by air blowing at 55 ℃ for 10 hours, thus obtaining the target compound 14, 14-D3-tetradecyl 14, 14-D3-tetradecylamide as a light white solid (1.77g, 93%).
APCI-MS:m/z 444[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 8.13(s,1H),3.86(m,2H),2.66(m,2H),1.58(m,4H), 1.35(m,4H),1.24(m,30H)。
4) Ext> Synthesisext> ofext> Next>,ext> Next> -ext> bisext> (ext> 14ext>,ext> 14ext> -ext> Dext> 3ext> -ext> tetradecylext>)ext> amineext> (ext> dPEGext> -ext> Aext> -ext> 6ext>)ext>
The molecular formula is as follows: c 29 H 55 D 6 N
Molecular weight 429.84
To a suspension of 14,14, 14-D3-tetradecyl-14, 14-D3-tetradecylamide (2g, 4.5mo1) in THF (20 mL) was added lithium aluminum hydride (0.51g, 13.5mmo1) in portions at room temperature. The mixture was heated to 68 ℃ and refluxed overnight. After the reaction was detected to be complete, the mixture was cooled to 0 ℃ and added with aqueous sodium hydroxide solution and stirred for 2h, filtered through a pad of celite and silica gel and washed with ether. The filtrate became cloudy and a precipitate formed, which was stirred for 5min and filtered to give a white solid.
Ext> transferringext> theext> whiteext> solidext> intoext> aext> 20ext> mlext> doubleext> -ext> mouthext> bottleext>,ext> addingext> 5ext> mlext> ofext> methanolext>,ext> heatingext> toext> 60ext> ℃ext> forext> dissolvingext>,ext> coolingext> toext> 25ext> ℃ext> afterext> 30ext> minext>,ext> stirringext> forext> crystallizationext> forext> 10ext> hoursext>,ext> filteringext>,ext> leachingext> withext> 1ext> mlext> ofext> methanolext>,ext> andext> dryingext> theext> solidext> atext> 55ext> ℃ext> forext> 10ext> hoursext> toext> obtainext> Next>,ext> Next> -ext> diext> (ext> 14ext>,ext> 14ext> -ext> Dext> 3ext> -ext> tetradecylext>)ext> amineext> (ext> dPEGext> -ext> Aext> -ext> 6ext>)ext> asext> aext> whiteext> solidext> (ext> 1.45gext>,ext> 75.01ext>%ext>)ext>.ext>
APCI-MS:m/z 430[M+H]+
1 H-NMR(300MHz,DMSO-d6):δppm 3.45(s,1H),2.66(m,4H),1.58(m,4H),1.35(m, 4H),1.24(m,44H)。
5) Ext> Synthesisext> ofext> Next>,ext> Next> -ext> bisext> (ext> 14ext>,ext> 14ext> -ext> Dext> 3ext> -ext> tetradecylext>)ext> -ext> 2ext>,ext> 2ext> -ext> 2ext> Dext> -ext> 2ext> -ext> methylpolyethyleneglycolext> acetamideext> (ext> dPEGext> -ext> Aext>)ext>
The molecular formula is as follows: c 117 H 231 D 8 NO 47
Molecular weight: 2485
To a 50mL two-necked flask was added a solution of N, N-bis (14,14,14-D3-tetradecyl) amine (2g, 4.65mmol) and triethylamine (0.71 g, 6.98 mmol) in DCM (40 mL) was added a solution of methyl polyethylene glycol succinimide acetate (mPEG-NHS, 4.65mml,10.1g, PEG MW about 2,000,n = about 45) in DCM (50 m). After stirring at room temperature 3 for 24h, water (30 mL) was added and the aqueous phase was extracted twice with DCM (100 mLx 2). The DCM extracts were combined and washed with 1M HCl (30 mL). After drying the organic phase over sodium sulfate, filtration and concentration of the remaining approximately 30m1 of the organic phase, it was cooled to-20 ℃ and stirred for 8 hours, filtered and rinsed with 3ml of DCM to give a white solid (0.9 g, unreacted starting amine), to which was added triethylamine (18.6 mmol) and acetic anhydride (1.4 mmol, 143mg), and after 10min there was a solid which precipitated and stirred at room temperature for 5 hours, then concentrated to a solid at 40 ℃ and the remaining solid was purified by column chromatography on silica gel (DCM containing 0-8% methanol) to give N, N-bis (14, 14-D3-tetradecyl) -2, 2-2D-2-methylpolyethyleneglycol acetamide as a white solid (5.82 g, yield approximately 50%).
APCI-MS:m/z 2486[M+H] +
1 H-NMR(300MHz,CDC13):δppm 3.83-3.465(m,180-200H),3.39(s,3H),3.28(m,4H), 1.58(m,4H),1.35(m,4H),1.24(m,44H)。
Example 2
Representative synthetic routes
Compound B3- (2-2-Methylpolyethyleneglycol (n = 45)) -1, 2-diyl-bis (14, 14-3D-tetradecylcarboxy) 1,2, 3-5D-propane
1) Synthesis of 1,2, 3-3D-3-methyl polyethylene glycol-1, 2-propylene oxide
The molecular formula is as follows: c 94 H 183 D 5 O 47
Molecular weight: 2073
A mixed solution of polyethylene glycol monomethyl ether (dEG-B-2, 68.2g, PEG Mw of about 2000, n = about 45, 34.1mmol, 1.2eq) in THF (55 mL) and DMF (10 mL) was cooled at 0-10 deg.C, naH (60% by mass, 1.4g, 34.1mmol, 1.2eq) was added, the mixture was stirred at constant temperature for 0.5hr, a THF solution (10 mL) of 1,2, 3-3D-3-chloro-1, 2-epoxypropane (dEG-B-1, 2.8g,28.4mmol, 1.eq) was slowly added, and the mixture was stirred at room temperature for 18 hours after the addition. TLC showed that the dEG-B-1 was substantially complete, and the reaction was slowly poured into saturated ammonium chloride solution. THF was added and extraction was performed 3 times. The organic phases were combined and washed once with saturated sodium chloride. The organic phase was stirred with silica gel and purified by column chromatography (EA: PE =5, 1, rf = 0.4) to give 39.2g of semi-oil semisolid with a yield of 65%.
APCI-MS:m/z 2074[M+H] +
1 H-NMR(300MHz,CDC13):δppm 3.83-3.46(m,180-200H),3.39(s,3H)。
2) Synthesis of 1,2, 3-3D-3-methyl polyethylene glycol-1, 2-propanediol
The molecular formula is as follows: c 94 H 185 D 5 O 48
Molecular weight: 2091
1,2, 3-3D-3-methyl polyethylene glycol-1, 2-propylene oxide (39.2g, 18.9mmol) is dissolved in 500ml tetrahydrofuran, 2M sodium hydroxide solution (1.13g, 28.35mmol, 14.16ml) is added, the temperature is raised to 50 ℃ and stirred for 6 hours, after the detection of the reaction of the raw materials, the temperature is lowered to room temperature, EA extraction is carried out for 1 time, saturated sodium chloride is used for washing an organic phase silica gel sample for one time, and column chromatography purification (EA) is carried out to obtain 38.7g of white solid with the yield of 97.7%.
APCI-MS:m/z 2092[M+H] +
1 H-NMR(300MHz,CDC13):δppm 6.10(s,1H),5.08(s,1H),3.83-3.46(m,180-200H),3.39(s, 3H)。
3) Synthesis of 3- (2-2-methyl polyethylene glycol (n = 45)) -1, 2-diyl-bis (14, 14-3D-tetradecyloxy) 1,2, 3-5D-propane
The molecular formula is as follows: c 122 H 231 D 11 O 50
Molecular weight: 2517
38.7g of 1,2, 3-3D-3-methyl polyethylene glycol-based-1, 2-propanediol (dPEG-B-4, 18.50 mmol) was put into a 1000ml four-necked bottle, 400ml of DMF was added, 14-D3-myristic acid (8.99g, 38.85mmol) was added, DIEA (5.62g, 55.5 mmol) and EDCI (10.64g, 55.5 mmol) were added, the temperature was raised to 45 ℃ to react for 5 hours, after completion of the detection reaction, EA was extracted three times, washed once with water, washed once with brine, the organic phase was concentrated at 45 ℃ and purified by column chromatography (EA: PE = 15): 76.46 percent.
APCI-MS:m/z 2518[M+H] +
1 H-NMR(300MHz,CDC 13 ):δppm 3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m, 4H),1.38(m,4H),1.31(m,4H),1.26(m,32H)。
The following compounds can be prepared by employing the techniques described above and the associated procedures well known to those skilled in the art, and using appropriate deuterated reagents.
EXAMPLE 3 Synthesis of Compound 2
The molecular formula is as follows: C117H232D7NO47
Molecular weight: 2484
APCI-MS:m/z 2485[M+H]+
1H-NMR(300MHz,DMSO-d6):δppm 4.23(s,1H),3.83-3.465(m,180-200H),3.39(s,3H), 3.28(m,4H),1.58(m,4H),1.35(m,4H),1.24(m,44H)。
EXAMPLE 4 Synthesis of Compound 3
The molecular formula is as follows: c 117 H 232 D 7 NO 47
Molecular weight: 2484
APCI-MS:m/z 2485[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 3.83-3.465(m,180-200H),3.39(s,3H),3.28(m,4H), 1.58(m,4H),1.35(m,5H),1.24(m,44H)。
EXAMPLE 5 Synthesis of Compound 4
The molecular formula is as follows: c 117 H 233 D 6 NO 47
Molecular weight: 2483
APCI-MS:m/z 2484[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.23(s,2H),3.83-3.465(m,180-200H),3.39(s,3H), 3.28(m,4H),1.58(m,4H),1.35(m,4H),1.24(m,44H)。
The molecular formula is as follows: c 117 H 233 D 6 NO 47
Molecular weight: 2483
APCI-MS:m/z 2484[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.23(s,1H),3.83-3.465(m,180-200H),3.39(s,3H), 3.28(m,4H),1.58(m,4H),1.35(m,5H),1.24(m,44H)。
EXAMPLE 7 Synthesis of Compound 6
The molecular formula is as follows: c 117 H 233 D 6 NO 47
Molecular weight: 2483
APCI-MS:m/z 2484[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 3.83-3.465(m,180-200H),3.39(s,3H),3.28(m,4H), 1.58(m,4H),1.35(m,6H),1.24(m,44H)。
EXAMPLE 8 Synthesis of Compound 7
The molecular formula is as follows: c 117 H 234 D 5 NO 47
Molecular weight: 2482
APCI-MS:m/z 2483[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm3.83-3.465(m,180-200H),3.39(s,3H),3.28(m,4H), 1.58(m,4H),1.35(m,2H),1.24(m,46H),0.88(m,3H)。
EXAMPLE 9 Synthesis of Compound 8
Molecular formula:C 117 H 234 D 5 NO 47
Molecular weight: 2482
APCI-MS:m/z 2483[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.56(s,2H),3.83-3.465(m,180-200H),3.39(s,3H), 3.28(m,4H),1.58(m,4H),1.35(m,5H),1.24(m,44H)。
EXAMPLE 10 Synthesis of Compound 9
The molecular formula is as follows: c 117 H 234 D 5 NO 47
Molecular weight: 2482
APCI-MS:m/z 2483[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.56(s,1H),3.83-3.465(m,180-200H),3.39(s,3H), 3.28(m,4H),1.58(m,4H),1.35(m,6H),1.24(m,44H)。
EXAMPLE 11 Synthesis of Compound 10
The molecular formula is as follows: c 117 H 234 D 5 NO 47
Molecular weight: 2482
APCI-MS:m/z 2483[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.56(s,1H),3.83-3.465(m,180-200H),3.39(s,3H), 3.28(m,4H),1.58(m,4H),1.35(m,2H),1.24(m,44H),0.89(m,3H)。
EXAMPLE 12 Synthesis of Compound 11
The molecular formula is as follows: c 117 H 235 D 4 NO 47
Molecular weight: 2482
APCI-MS:m/z 2482[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.56(s,1H),3.83-3.465(m,180-200H),3.39(s,3H), 3.28(m,4H),1.58(m,4H),1.35(m,6H),1.24(m,44H)。
EXAMPLE 13 Synthesis of Compound 12
The molecular formula is as follows: c 117 H 235 D 4 NO 47
Molecular weight: 2481
APCI-MS:m/z 2482[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 3.83-3.465(m,180-200H),3.39(s,3H),3.28(m,4H), 1.58(m,4H),1.35(m,8H),1.24(m,44H)。
The molecular formula is as follows: c 117 H 235 D 4 NO 47
Molecular weight: 2481
APCI-MS:m/z 2482[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 3.83-3.465(m,180-200H),3.39(s,3H),3.28(m,4H), 1.58(m,4H),1.35(m,3H),1.24(m,46H),0.90(m,3H)。
EXAMPLE 15 Synthesis of Compound 14
The molecular formula is as follows: c 117 H 236 D 3 NO 47
Molecular weight: 2481
APCI-MS:m/z 2482[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.62(s,2H),3.83-3.465(m,180-200H),3.39(s,3H), 3.28(m,4H),1.58(m,4H),1.35(m,2H),1.24(m,46H),0.90(m,3H)。
EXAMPLE 16 Synthesis of Compound 15
The molecular formula is as follows: c 117 H 236 D 3 NO 47
Molecular weight: 2481
APCI-MS:m/z 2482[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.62(s,2H),3.83-3.465(m,180-200H),3.39(s,3H), 3.28(m,4H),1.58(m,4H),1.35(m,7H),1.24(m,44H)。
EXAMPLE 17 Synthesis of Compound 16
The molecular formula is as follows: c 117 H 236 D 3 NO 47
Molecular weight: 2481
APCI-MS:m/z 2482[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.62(s,1H),3.83-3.465(m,180-200H),3.39(s,3H), 3.28(m,4H),1.58(m,4H),1.35(m,3H),1.24(m,46H),0.91(m,3H)。
EXAMPLE 18 Synthesis of Compound 17
The molecular formula is as follows: c 117 H 236 D 3 NO 47
Molecular weight: 2481
APCI-MS:m/z 2482[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.62(s,1H),3.83-3.465(m,180-200H),3.39(s,3H), 3.28(m,4H),1.58(m,4H),1.35(m,8H),1.24(m,44H)。
EXAMPLE 19 Synthesis of Compound 18
The molecular formula is as follows: c 117 H 236 D 3 NO 47
Molecular weight: 2481
APCI-MS:m/z 2482[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 3.83-3.465(m,180-200H),3.39(s,3H),3.28(m,4H), 1.58(m,4H),1.35(m,4H),1.24(m,46H),0.92(m,3H)。
EXAMPLE 20 Synthesis of Compound 19
The molecular formula is as follows: c 117 H 237 D 2 NO 47
Molecular weight: 2480
APCI-MS:m/z 2481[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 3.83-3.465(m,180-200H),3.39(s,3H),3.28(m,4H), 1.58(m,4H),1.24(m,48H),0.92(m,6H)。
EXAMPLE 21 Synthesis of Compound 20
The molecular formula is as follows: c 117 H 237 D 2 NO 47
Molecular weight: 2480
APCI-MS:m/z 2481[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.66(s,1H),3.83-3.465(m,180-200H),3.39(s,3H), 3.28(m,4H),1.58(m,4H),1.36(m,4H),1.24(m,46H),0.92(m,3H)。
EXAMPLE 22 Synthesis of Compound 21
The molecular formula is as follows: c 117 H 237 D 2 NO 47
Molecular weight: 2480
APCI-MS:m/z 2481[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.66(s,2H),3.83-3.465(m,180-200H),3.39(s,3H), 3.28(m,4H),1.58(m,4H),1.36(m,6H),1.24(m,44H)。
EXAMPLE 23 Synthesis of Compound 22
The molecular formula is as follows: c 117 H 237 D 2 NO 47
Molecular weight: 2480
APCI-MS:m/z 2481[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.66(s,2H),3.83-3.465(m,180-200H),3.39(s,3H), 3.28(m,4H),1.58(m,4H),1.36(m,3H),1.24(m,46H),0.92(m,3H)。
EXAMPLE 24 Synthesis of Compound 23
The molecular formula is as follows: c 117 H 238 D 1 NO 47
Molecular weight: 2479
APCI-MS:m/z 2480[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.66(s,1H),3.83-3.465(m,180-200H),3.39(s,3H), 3.28(m,4H),1.58(m,4H),1.24(m,48H),0.92(m,6H)。
EXAMPLE 25 Synthesis of Compound 24
The molecular formula is as follows: c 117 H 238 D 1 NO 47
Molecular weight: 2479
APCI-MS:m/z 2480[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.66(s,2H),3.83-3.465(m,180-200H),3.39(s,3H), 3.28(m,4H),1.58(m,4H),1.35(m,4H),1.24(m,46H),0.92(m,3H)。
EXAMPLE 26 Synthesis of Compound 26
The molecular formula is as follows: c 122 H 232 D 10 O 50
Molecular weight: 2516
APCI-MS:m/z 2517[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H), 1.69(m,4H),1.38(m,4H),1.31(m,5H),1.26(m,32H)。
EXAMPLE 27 Synthesis of Compound 27
The molecular formula is as follows: c 122 H 232 D 10 O 50
Molecular weight: 2516
APCI-MS:m/z 2517[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H), 1.69(m,4H),1.38(m,5H),1.31(m,4H),1.26(m,32H)。
EXAMPLE 28 Synthesis of Compound 28
The molecular formula is as follows: c 122 H 232 D 10 O 50
Molecular weight: 2516
APCI-MS:m/z 2517[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 5.6(s,1H),3.83-3.46(m,180-200H),3.39(s,3H), 2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,4H),1.26(m,32H)。
EXAMPLE 29 Synthesis of Compound 29
The molecular formula is as follows: c 122 H 232 D 10 O 50
Molecular weight: 2516
APCI-MS:m/z 2517[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 5.6(s,1H),3.83-3.46(m,180-200H),3.39(s,3H), 2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,4H),1.26(m,32H)。
EXAMPLE 30 Synthesis of Compound 30
The molecular formula is as follows: c 122 H 232 D 10 O 50
Molecular weight: 2516
APCI-MS:m/z 2517[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.65(s,1H),3.83-3.46(m,180-200H),3.39(s,3H), 2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,4H),1.26(m,32H)。
EXAMPLE 31 Synthesis of Compound 31
The molecular formula is as follows: c 122 H 233 D 9 O 50
Molecular weight: 2515
APCI-MS:m/z 2516[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H), 1.69(m,4H),1.38(m,6H),1.31(m,4H),1.26(m,32H)。
EXAMPLE 32 Synthesis of Compound 32
The molecular formula is as follows: c 122 H 233 D 9 O 50
Molecular weight: 2515
APCI-MS:m/z 2516[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H), 1.69(m,4H),1.38(m,6H),1.31(m,4H),1.26(m,32H)。
EXAMPLE 33 Synthesis of Compound 33
The molecular formula is as follows: c 122 H 233 D 9 O 50
Molecular weight: 2515
APCI-MS:m/z 2516[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 5.6(s,1H),3.83-3.46(m,180-200H),3.39(s,3H), 2.35(m,4H),1.69(m,4H),1.38(m,5H),1.31(m,4H),1.26(m,32H)。
EXAMPLE 34 Synthesis of Compound 34
The molecular formula is as follows: c 122 H 233 D 9 O 50
Molecular weight: 2515
APCI-MS:m/z 2516[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 5.6(s,1H),3.83-3.46(m,180-200H),3.39(s,3H), 2.35(m,4H),1.69(m,4H),1.38(m,5H),1.31(m,4H),1.26(m,32H)。
EXAMPLE 35 Synthesis of Compound 35
The molecular formula is as follows: c 122 H 233 D 9 O 50
Molecular weight: 2515
APCI-MS:m/z 2516[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 4.43(s,1H),3.83-3.46(m,180-200H),3.39(s,3H), 2.35(m,4H),1.69(m,4H),1.38(m,5H),1.31(m,4H),1.26(m,32H)。
EXAMPLE 36 Synthesis of Compound 36
The molecular formula is as follows: c 122 H 234 D 8 O 50
Molecular weight: 2514
APCI-MS:m/z 2515[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H), 1.69(m,4H),1.38(m,4H),1.31(m,2H),1.26(m,34H),0.92(m,3H)。
EXAMPLE 37 Synthesis of Compound 37
The molecular formula is as follows: c 122 H 234 D 8 O 50
Molecular weight: 2514
APCI-MS:m/z 2515[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 5.62(d,1H,J=5.6Hz),5.58(d,1H,J=5.6Hz),3.83-3.46 (m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,5H),1.26(m,32H)。
EXAMPLE 38 Synthesis of Compound 38
The molecular formula is as follows: c 122 H 234 D 8 O 50
Molecular weight: 2514
APCI-MS:m/z 2515[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 5.62(t,1H,J=8.3Hz),5.58(d,2H,J=5.3Hz),3.83-3.46 (m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,5H),1.31(m,4H),1.26(m,32H)。
EXAMPLE 39 Synthesis of Compound 39
The molecular formula is as follows: c 122 H 234 D 8 O 50
Molecular weight: 2514
APCI-MS:m/z 2515[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 5.62(s,2H),5.58(s,1H),3.83-3.46(m,180-200H), 3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,5H),1.31(m,4H),1.26(m,32H)。
EXAMPLE 40 Synthesis of Compound 40
The molecular formula is as follows: c 122 H 233 D 9 O 50
Molecular weight: 2515
APCI-MS:m/z 2516[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 5.62(s,1H),4.86(s,1H),3.83-3.46(m,180-200H), 3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,4H),1.26(m,32H)。
EXAMPLE 41 Synthesis of Compound 41
The molecular formula is as follows: c 122 H 235 D 7 O 50
Molecular weight: 2513
APCI-MS:m/z 2514[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H), 1.69(m,4H),1.38(m,4H),1.31(m,3H),1.26(m,34H),0.92(s,3H)。
EXAMPLE 42 Synthesis of Compound 42
The molecular formula is as follows: c 122 H 235 D 7 O 50
Molecular weight: 2513
APCI-MS:m/z 2514[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 5.56(s,1H),3.83-3.46(m,180-200H),3.39(s,3H), 2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,5H),1.26(m,32H)。
EXAMPLE 43 Synthesis of Compound 43
The molecular formula is as follows: c 122 H 235 D 7 O 50
Molecular weight: 2513
APCI-MS:m/z 2514[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 5.56(d,1H,J=5.5Hz),5.49(d,1H,J=5.5Hz),3.83-3.46 (m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,6H),1.26(m,32H)。
EXAMPLE 44 Synthesis of Compound 44
The molecular formula is as follows: c 122 H 235 D 7 O 50
Molecular weight: 2513
APCI-MS:m/z 2514[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 5.56(t,1H,J=8.9Hz),5.49(d,1H,J=5.5Hz),4.87(d,1H, J=4.3Hz),3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m, 5H),1.26(m,32H)。
EXAMPLE 45 Synthesis of Compound 45
The molecular formula is as follows: c 122 H 235 D 7 O 50
Molecular weight: 2513
APCI-MS:m/z 2514[M+H] +
1 H-NMR(300MHz,DMSO-d6):δppm 5.56(t,1H,J=8.9Hz),5.49(d,1H,J=5.5Hz),4.87(d,1H, J=4.3Hz),3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m, 5H),1.26(m,32H)。
EXAMPLE 46 Synthesis of Compound 46
The molecular formula is as follows: c 122 H 235 D 7 O 50
Molecular weight: 2513
APCI-MS:m/z 2514[M+H] +
1 H-NMR(300MHz,DMSO-d6):3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m, 4H),1.38(m,4H),1.31(m,3H),1.26(m,34H),0.93(m,3H)。
EXAMPLE 47 Synthesis of Compound 47
The molecular formula is as follows: c 122 H 236 D 6 O 50
Molecular weight: 2512
APCI-MS:m/z 2513[M+H] +
1 H-NMR(300MHz,DMSO-d6):3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m, 4H),1.38(m,4H),1.31(m,4H),1.26(m,34H),0.93(m,3H)。
EXAMPLE 48 Synthesis of Compound 48
The molecular formula is as follows: c 122 H 236 D 6 O 50
Molecular weight: 2512
APCI-MS:m/z 2513[M+H] +
1 H-NMR(300MHz,DMSO-d6):3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m, 4H),1.38(m,4H),1.31(m,4H),1.26(m,34H),0.93(m,3H)。
EXAMPLE 49 Synthesis of Compound 49
The molecular formula is as follows: c 122 H 236 D 6 O 50
Molecular weight: 2512
APCI-MS:m/z 2513[M+H] +
1 H-NMR(300MHz,DMSO-d6):4.65(s,2H),3.83-3.46(m,180-200H),3.39(s,3H),2.35(m, 4H),1.69(m,4H),1.38(m,4H),1.31(m,2H),1.26(m,34H),0.93(m,3H)。
EXAMPLE 50 Synthesis of Compound 50
The molecular formula is as follows: c 122 H 236 D 6 O 50
Molecular weight: 2512
APCI-MS:m/z 2513[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.62(d,1H,J=6.8Hz),4.65(d,1H,J=3.2Hz),3.83-3.46(m, 180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,2H),1.26(m,34H), 0.93(m,3H)。
EXAMPLE 51 Synthesis of Compound 51
The molecular formula is as follows: c 122 H 236 D 6 O 50
Molecular weight: 2512
APCI-MS:m/z 2513[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.72(d,1H,J=8.9Hz),4.65(d,1H,J=3.2Hz),3.83-3.46(m, 180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,2H),1.26(m,34H), 0.93(m,3H)。
EXAMPLE 52 Synthesis of Compound 52
The molecular formula is as follows: c 122 H 236 D 6 O 50
Molecular weight: 2512
APCI-MS:m/z 2513[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.78(m,1H),5.63(d,2H,J=8.6Hz),4.65(d,2H,J=3.8Hz), 3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,4H),1.26(m, 32H)。
EXAMPLE 53 Synthesis of Compound 53
The molecular formula is as follows: c 122 H 237 D 5 O 50
Molecular weight: 2511
APCI-MS:m/z 2512[M+H] +
1 H-NMR(300MHz,DMSO-d6):3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m, 4H),1.38(m,4H),1.26(m,36H),0.93(m,6H)。
EXAMPLE 54 Synthesis of Compound 54
The molecular formula is as follows: c 122 H 237 D 5 O 50
Molecular weight: 2511
APCI-MS:m/z 2512[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.62(m,1H),3.83-3.46(m,180-200H),3.39(s,3H),2.35(m, 4H),1.69(m,4H),1.38(m,4H),1.31(m,4H),1.26(m,34H),0.93(m,3H)。
EXAMPLE 55 Synthesis of Compound 55
The molecular formula is as follows: c 122 H 237 D 5 O 50
Molecular weight: 2511
APCI-MS:m/z 2512[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.62(t,1H,J=7.98Hz),4.68(d,2H,J=3.59Hz),3.83-3.46(m, 180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,2H),1.26(m,34H), 0.93(m,3H)。
EXAMPLE 56 Synthesis of Compound 56
The molecular formula is as follows: c 122 H 237 D 5 O 50
Molecular weight: 2511
APCI-MS:m/z 2512[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.62(d,1H,J=6.5Hz),5.58(d,1H,J=6.3Hz),4.68(d,2H, J=3.59Hz),3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m, 2H),1.26(m,34H),0.93(m,3H)。
EXAMPLE 57 Synthesis of Compound 57
The molecular formula is as follows: c 122 H 237 D 5 O 50
Molecular weight: 2511
APCI-MS:m/z 2512[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.62(d,1H,J=6.5Hz),4.68(d,2H,J=3.59Hz),3.83-3.46(m, 180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,8H),1.26(m,32H)。
EXAMPLE 58 Synthesis of Compound 58
The molecular formula is as follows: c 122 H 238 D 4 O 50
Molecular weight: 2510
APCI-MS:m/z 2511[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.62(s,1H),3.83-3.46(m,180-200H),3.39(s,3H),2.35(m, 4H),1.69(m,4H),1.38(m,4H),1.26(m,36H),0.93(m,6H)。
EXAMPLE 59 Synthesis of Compound 59
The molecular formula is as follows: c 122 H 238 D 4 O 50
Molecular weight: 2510
APCI-MS:m/z 2511[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.62(d,1H,J=5.2Hz),5.59(d,1H,J=6.6Hz)3.83-3.46(m, 180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,4H)1.26(m,34H),0.93(m, 3H)。
EXAMPLE 60 Synthesis of Compound 60
The molecular formula is as follows: c 122 H 238 D 4 O 50
Molecular weight: 2510
APCI-MS:m/z 2511[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.62(t,1H,J=8.6Hz),5.59(d,1H,J=6.6Hz)4.86(d,1H, J=3.8Hz),3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m, 8H),1.26(m,32H)。
EXAMPLE 61 Synthesis of Compound 61
The molecular formula is as follows: c 122 H 238 D 4 O 50
Molecular weight: 2510
APCI-MS:m/z 2511[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.62(m,1H),5.59(d,2H,J=6.6Hz)4.86(d,2H,J=3.8Hz), 3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,6H),1.26(m, 32H)。
EXAMPLE 62 Synthesis of Compound 62
The molecular formula is as follows: c 122 H 238 D 4 O 50
Molecular weight: 2510
APCI-MS:m/z 2511[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.59(s,2H),4.86(s,2H),3.83-3.46(m,180-200H),3.39(s, 3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,2H),1.26(m,34H),0.94(m,3H)。
EXAMPLE 63 Synthesis of Compound 63
The molecular formula is as follows: c 122 H 239 D 3 O 50
Molecular weight: 2509
APCI-MS:m/z 2510[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.65(d,1H,J=8.4Hz),4.83(d,1H,J=3.9Hz),3.83-3.46(m, 180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.26(m,36H),0.94(m,6H)。
EXAMPLE 64 Synthesis of Compound 64
The molecular formula is as follows: c 122 H 239 D 3 O 50
Molecular weight: 2509
APCI-MS:m/z 2510[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.65(m,1H),5.58(d,2H,J=6.9Hz),4.83(d,2H,J=3.9Hz), 3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,2H),1.26(m, 34H),0.94(m,4H)。
EXAMPLE 65 Synthesis of Compound 65
The molecular formula is as follows: c 122 H 239 D 3 O 50
Molecular weight: 2509
APCI-MS:m/z 2510[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.65(m,1H),5.58(d,2H,J=6.9Hz),4.83(d,2H,J=3.9Hz), 3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,2H),1.26(m, 34H),0.94(m,4H)。
EXAMPLE 66 Synthesis of Compound 66
The molecular formula is as follows: c 122 H 239 D 3 O 50
Molecular weight: 2509
APCI-MS:m/z 2510[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.65(m,1H),5.58(d,2H,J=6.9Hz),4.83(d,2H,J=3.9Hz), 3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,7H),1.26(m, 32H)。
EXAMPLE 67 Synthesis of Compound 67
The molecular formula is as follows: c 122 H 238 D 4 O 50
Molecular weight: 2510
APCI-MS:m/z 2511[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.65(m,1H),5.58(d,2H,J=6.9Hz),4.83(d,2H,J=3.9Hz), 3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,6H),1.26(m, 32H)。
EXAMPLE 69 Synthesis of Compound 68
The molecular formula is as follows: c 122 H 238 D 4 O 50
Molecular weight: 2510
APCI-MS:m/z 2511[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.65(d,1H,J=6.6Hz),4.83(d,2H,J=3.9Hz),3.83-3.46(m, 180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,3H),1.26(m,34H),0.95(m, 3H)。
EXAMPLE 69 Synthesis of Compound 69
The molecular formula is as follows: c 122 H 238 D 4 O 50
Molecular weight: 2510
APCI-MS:m/z 2511[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.68(t,1H,J=8.9Hz),5.65(d,1H,J=6.6Hz),3.83-3.46(m, 180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,3H),1.26(m,34H),0.95(m, 3H)。
EXAMPLE 70 Synthesis of Compound 70
The molecular formula is as follows: c 122 H 238 D 4 O 50
Molecular weight: 2510
APCI-MS:m/z 2511[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.65(s,1H),4.69(s,2H),3.83-3.46(m,180-200H),3.39(s, 3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,4H),1.26(m,34H),0.95(m,3H)。
EXAMPLE 71 Synthesis of Compound 71
The molecular formula is as follows: c 122 H 238 D 4 O 50
Molecular weight: 2510
APCI-MS:m/z 2511[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.56(s,2H),4.69(s,2H),3.83-3.46(m,180-200H),3.39(s, 3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.31(m,7H),1.26(m,32H)。
EXAMPLE 72 Synthesis of Compound 72
The molecular formula is as follows: c 122 H 240 D 2 O 50
Molecular weight: 2508
APCI-MS:m/z 2509[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.61(t,1H,J=8.3Hz),4.66(d,2H,J=7.8Hz),3.83-3.46(m, 180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.26(m,36H),0.96(m,6H)。
EXAMPLE 73 Synthesis of Compound 73
The molecular formula is as follows: c 122 H 240 D 2 O 50
Molecular weight: 2508
APCI-MS:m/z 2509[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.79(m,1H),5.66(d,2H,J=7.6Hz),4.61(d,2H,J=7.3Hz), 3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.32(m,3H), 1.26(m,34H),0.96(m,3H)。
EXAMPLE 74 Synthesis of Compound 74
The molecular formula is as follows: c 122 H 240 D 2 O 50
Molecular weight: 2508
APCI-MS:m/z 2509[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.79(m,1H),5.66(d,2H,J=7.6Hz),4.61(d,2H,J=7.3Hz), 3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.32(m,3H), 1.26(m,34H),0.96(m,3H)。
EXAMPLE 75 Synthesis of Compound 75
The molecular formula is as follows: c 122 H 240 D 2 O 50
Molecular weight: 2508
APCI-MS:m/z 2509[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.79(m,1H),5.66(d,2H,J=7.6Hz),4.61(d,2H,J=7.3Hz), 3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.32(m, 8H),1.26(m,32H)。
EXAMPLE 76 Synthesis of Compound 76
The molecular formula is as follows: c 122 H 240 D 2 O 50
Molecular weight: 2508
APCI-MS:m/z 2509[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.66(s,2H,),4.61(s,2H),3.83-3.46(m,180-200H),3.39(s, 3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.32(m,4H),1.26(m,34H),0.93(m,3H)。
EXAMPLE 77 Synthesis of Compound 77
The molecular formula is as follows: c 122 H 240 D 2 O 50
Molecular weight: 2508
APCI-MS:m/z 2509[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.70(q,1H,J 1 =9.6Hz,J 2 =3.8Hz),5.66(d,1H,J=7.3Hz), 4.61(d,2H,J=7.3Hz),3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m, 4H),1.32(m,4H),1.26(m,34H),0.93(m,3H)。
EXAMPLE 78 Synthesis of Compound 78
The molecular formula is as follows: c 122 H 241 D 1 O 50
Molecular weight: 2507
APCI-MS:m/z 2508[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.70(q,1H,J 1 =9.6Hz,J 2 =3.8Hz),5.69(d,1H,J=7.3Hz), 4.63(d,2H,J=3.9Hz),3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m, 4H),1.26(m,36H),0.93(m,6H)。
EXAMPLE 79 Synthesis of Compound 79
The molecular formula is as follows: c 122 H 241 D 1 O 50
Molecular weight: 2507
APCI-MS:m/z 2508[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.69(s,2H),4.63(s,2H),3.83-3.46(m,180-200H),3.39(s, 3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.26(m,36H),0.93(m,6H)。
EXAMPLE 80 Synthesis of Compound 80
The molecular formula is as follows: c 122 H 241 D 1 O 50
Molecular weight: 2507
APCI-MS:m/z 2508[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.70(q,1H,J 1 =9.1Hz,J 2 =42.1Hz),5.69(d,2H,J=5.9Hz), 4.63(d,1H,J=3.9Hz),3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m, 4H),1.26(m,36H),0.93(m,6H)。
EXAMPLE 81 Synthesis of Compound 81
The molecular formula is as follows: c 122 H 241 D 1 O 50
Molecular weight: 2507
APCI-MS:m/z 2508[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.70(m,1H),5.69(d,2H,J=5.9Hz),4.63(d,1H,J=3.9Hz), 3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.32(m,3H), 1.26(m,34H),0.93(m,6H)。
EXAMPLE 82 Synthesis of Compound 82
The molecular formula is as follows: c 122 H 241 D 1 O 50
Molecular weight: 2507
APCI-MS:m/z 2508[M+H] +
1 H-NMR(300MHz,DMSO-d6):5.70(m,1H),5.69(d,2H,J=5.9Hz),4.63(d,1H,J=3.9Hz), 3.83-3.46(m,180-200H),3.39(s,3H),2.35(m,4H),1.69(m,4H),1.38(m,4H),1.32(m,3H), 1.26(m,34H),0.93(m,6H)。
Example 83
Luciferase mRNA in vivo evaluation using lipid nanoparticle compositions
Dissolving a cationic lipid, DSPC, cholesterol, and a deuterated PEG-lipid in ethanol at a molar ratio of 50. Lipid Nanoparticles (LNPs) were prepared at a weight ratio of total lipid to mRNA of about 10. Briefly, mRNA was diluted to 0.15mg/mL in 10mL to 50mL citrate buffer (pH = 4). The lipid ethanol solution and the mRNA aqueous solution were mixed using a syringe pump at a ratio of about 1 to 1 (volume/volume) in the range of 10ml/min or more for the total flow rate. The ethanol was then removed and the external buffer was replaced with PBS by dialysis. Finally, the lipid nanoparticles were filtered through a sterile filter with a pore size of 0.2 μm. The particle size of the lipid nanoparticles, as determined by quasielastic light scattering using a Malvern Zetasizer Nano ZS, is about 65-105nm in diameter, and in some cases, about 75-100nm in diameter.
R 1 ,R 2 ,R 3 ,R4,R 5 ,R 6 ,R 7 R8 are each independently 2 "hydrogen" isotopes (including hydrogen, deuterium), embodied as a combination of "HH", "HD" and "DD"
R 1 ,R 2 ,R 3 ,R4,R 5 ,R 6 ,R 7 R8 are each independently 2 "hydrogen" isotopes (including hydrogen, deuterium), embodied as a combination of "HH", "HD", and "DD".
The study was performed on 6-8 week old female C57BL/6 mice, 8-10 week old CD-1 mice, according to the guidelines set by the national institute of science and technology. Different doses of mRNA lipid nanoparticles were administered systemically by tail vein injection and animals were euthanized at specific time points (e.g., 5 hours) after administration. Liver and spleen were collected in pre-weighed tubes, weighed, immediately snap frozen in liquid nitrogen, and stored at-80 ℃ until used for analysis.
For the liver, approximately 50mg was cut for analysis in 2mL FastPrep tubes (MP Biomedicals, solon OH). 1/4 "ceramic spheres (MP Biomedicals) were added to each tube, and 500. Mu.L of Glo lysis buffer-GLB (Promega, madison Wis.) equilibrated to room temperature was added to the liver tissue. Liver tissue was homogenized using a FastPrep24 instrument (MP Biomedicals) at 2X 6.0m/s for 15 seconds. The homogenate was incubated at room temperature for 5min, then diluted 1. Specifically, 50. Mu.L of the diluted tissue homogenate was reacted with 50. Mu.L of SteadyGlo substrate, shaken for 10 seconds, followed by incubation for 5 minutes, and then quantified using a SpectraMAX _ L chemiluminescence-type microplate reader (Meigu Motors, inc.). The amount of protein determined was determined by using BCA protein quantification kit (shanghai chromophil medical science and technology ltd). Relative Luminescence Units (RLU) were then normalized to the total μ g of protein assayed. To convert RLU to μ g luciferase, a standard curve was generated with QuantiLum recombinant luciferase (Promega).
Fluciferase protein will be expressed by Fluuc mRNA from Trilink Biotechnologies (L-6107), which was originally isolated from fireflies (Photinus pyralis). Fluc is commonly used in mammalian cell cultures to measure gene expression and cell viability. Which emits bioluminescence in the presence of the substrate luciferin. This capped and polyadenylated mRNA was completely replaced by 5-methylcytidine and pseudouridine.
Example 84
Determination of pKa of the prepared lipid
The pKa of the formulated cationic lipid correlates with the effect of the LNP used to deliver the nucleic acid. The preferred pKa range is from 5 to 7. The pKa of each cationic lipid was determined in lipid nanoparticles using an assay based on the fluorescence of 2- (p-toluidinyl) -6-naphthalenesulfonic acid (TNS). Lipid nanoparticles comprising cationic lipids/DSPC/cholesterol/PEG lipids (50/10/38/2 mol%) at a concentration of 0.4mM total lipid in PBS were prepared using an ordered method as described in example 3. TNS was prepared as a 100 μ M stock solution in distilled water. The vesicles were diluted to 24. Mu.M lipid in 2mL of buffer containing 10mM HEPES, 10mM MES, 10mM acetic acid, 130mM NaCl, pH 2.5-11. Aliquots of the TNS solution were added to give a final concentration of l μ M and after vortex mixing the fluorescence intensity was measured in a SLM Aminco Series 2 luminescence spectrophotometer at room temperature using excitation and emission wavelengths of 321nm and 445 nm. Sigmoidal best fit analysis was applied to the fluorescence data and pKa was measured as the pH yielding half the maximum fluorescence intensity.
Example 85
Determination of the efficacy of lipid nanoparticle formulations containing various cationic lipids using rodent models of luciferase mRNA expression in vivo
For comparison purposes, these lipids were also used to formulate lipid nanoparticles containing FLuc mRNA (L-6107) using an ordered mixing method, as described in example 83. Lipid nanoparticles were formulated using a molar ratio of 50% cationic lipid/10% Distearoylphosphatidylcholine (DSPC)/38% cholesterol/2% deuterated PEG lipid. Relative activity was determined by measuring luciferase expression in the liver 5 hours after administration via tail vein injection as described in example 83. The activities were compared at doses of 0.3 and 1.0mg mRNA/kg and expressed as ng luciferase/g liver measured 5 hours after administration as described in example 83. The results of examples 83 and 84 are shown in Table 2.
Table 2 potency study of mRNA compositions comprising novel PEG lipids
The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.
The above-described embodiments are merely illustrative of several embodiments of the present invention, which are described in more detail and detail, but are not to be construed as limiting the scope of the disclosure. It should be noted that various changes and modifications can be made by those skilled in the art without departing from the spirit of the invention, and these changes and modifications are all within the scope of the invention. Therefore, the protection scope of the present invention should be subject to the appended claims.
Claims (25)
2. The deuterated polyethylene glycol lipid as set forth in claim 1, R 1 、R 2 、R 3 All have independence when R is 1 And R 2 When both are "HHH", R 3 Can not be "HH", when R 3 In the form of a "HH" combination, R 1 、R 2 One of which cannot be a HHH combination.
3. The deuterated polyethylene glycol lipid as recited in claims 1-2, R 1 、R 2 、R 3 Independently from each other, DDD, DD.
4. Deuterated polyethylene glycol lipid as recited in claim 1, wherein n has an average value of 40 to 50, preferably 45.
5. The method for preparing deuterated methyl polyethylene glycol compounds as recited in claims 1-2, wherein the method comprises the following steps:
1) Ext>ext> underext>ext> theext>ext> actionext>ext> ofext>ext> anext>ext> acylext>ext> chlorideext>ext> reagentext>ext>,ext>ext> aext>ext> deuteratedext>ext> generalext>ext> formulaext>ext> compoundext>ext> dPEGext>ext> -ext>ext> Aext>ext> -ext>ext> 1ext>ext> firstlyext>ext> generatesext>ext> acylext>ext> chlorideext>ext>,ext>ext> andext>ext> thenext>ext> performsext>ext> amidationext>ext> reactionext>ext> underext>ext> theext>ext> actionext>ext> ofext>ext> ammoniaext>ext> waterext>ext> toext>ext> obtainext>ext> aext>ext> deuteratedext>ext> generalext>ext> formulaext>ext> intermediateext>ext> dPEGext>ext> -ext>ext> Aext>ext> -ext>ext> 3ext>ext>;ext>ext>
2) Ext>ext> underext>ext> theext>ext> actionext>ext> ofext>ext> aext>ext> reducingext>ext> agentext>ext>,ext>ext> carryingext>ext> outext>ext> reductionext>ext> reactionext>ext> onext>ext> aext>ext> deuteratedext>ext> generalext>ext> -ext>ext> formulaext>ext> intermediateext>ext> dPEGext>ext> -ext>ext> Aext>ext> -ext>ext> 3ext>ext> toext>ext> obtainext>ext> aext>ext> deuteratedext>ext> generalext>ext> -ext>ext> formulaext>ext> intermediateext>ext> dPEGext>ext> -ext>ext> Aext>ext> -ext>ext> 4ext>ext>;ext>ext>
3) Ext>ext>ext> performingext>ext>ext> amidationext>ext>ext> reactionext>ext>ext> onext>ext>ext> theext>ext>ext> deuteratedext>ext>ext> generalext>ext>ext> formulaext>ext>ext> intermediateext>ext>ext> dPEGext>ext>ext> -ext>ext>ext> Aext>ext>ext> -ext>ext>ext> 4ext>ext>ext> andext>ext>ext> theext>ext>ext> generalext>ext>ext> formulaext>ext>ext> intermediateext>ext>ext> dPEGext>ext>ext> -ext>ext>ext> Aext>ext>ext> -ext>ext>ext> 1ext>ext>ext> accordingext>ext>ext> toext>ext>ext> theext>ext>ext> methodext>ext>ext> inext>ext>ext> theext>ext>ext> stepext>ext>ext> 1ext>ext>ext>)ext>ext>ext> toext>ext>ext> obtainext>ext>ext> aext>ext>ext> deuteratedext>ext>ext> generalext>ext>ext> formulaext>ext>ext> intermediateext>ext>ext> dPEGext>ext>ext> -ext>ext>ext> Aext>ext>ext> -ext>ext>ext> 5ext>ext>ext>;ext>ext>ext>
4) Ext>ext> accordingext>ext> toext>ext> theext>ext> methodext>ext> ofext>ext> theext>ext> stepext>ext> 2ext>ext>)ext>ext>,ext>ext> carryingext>ext> outext>ext> reductionext>ext> reactionext>ext> onext>ext> theext>ext> intermediateext>ext> dPEGext>ext> -ext>ext> Aext>ext> -ext>ext> 5ext>ext> withext>ext> theext>ext> deuteratedext>ext> generalext>ext> formulaext>ext> toext>ext> obtainext>ext> anext>ext> intermediateext>ext> dPEGext>ext> -ext>ext> Aext>ext> -ext>ext> 6ext>ext> withext>ext> theext>ext> deuteratedext>ext> generalext>ext> formulaext>ext>;ext>ext>
5) Ext>ext> inext>ext> anext>ext> organicext>ext> solventext>ext>,ext>ext> carryingext>ext> outext>ext> amidationext>ext> reactionext>ext> onext>ext> aext>ext> deuteratedext>ext> generalext>ext> formulaext>ext> intermediateext>ext> dPEGext>ext> -ext>ext> Aext>ext> -ext>ext> 6ext>ext> andext>ext> aext>ext> deuteratedext>ext> generalext>ext> formulaext>ext> compoundext>ext> dPEGext>ext> -ext>ext> Aext>ext> -ext>ext> 7ext>ext> underext>ext> theext>ext> actionext>ext> ofext>ext> baseext>ext> catalysisext>ext> toext>ext> obtainext>ext> aext>ext> deuteratedext>ext> polyethyleneext>ext> glycolext>ext> lipidext>ext> compoundext>ext> withext>ext> aext>ext> generalext>ext> formulaext>ext> Aext>ext>;ext>ext>
Synthetic route of general formula A.
7. The deuterated polyethylene glycol lipid as recited in claim 6, R 1 、R 2 、R 3 R4 and R5 are independent, when R is 1 、R 2 Are all "HHH" combinations, R 4 In the case of the "H" combination, R 3 、R 5 Cannot be simultaneously "HH"; when R is 3 、R 5 Are all "HH" combinations, R 4 In the case of the "H" combination, R 1 、R 2 Cannot be simultaneously combined as "HHH"; when R is 1 、R 2 Are all "HHH" combinations, R 3 、R 5 All in combination of "HH", R 4 It cannot be an "H" combination.
8. The deuterated polyethylene glycol lipid of claim 6, R 1 、R 2 、R 3 、R 4 、R 5 Each independently a combination of "DDD", "DD", "D".
9. The deuterated polyethylene glycol lipid as recited in claim 6, wherein n has an average value of 40 to 50, preferably 45.
10. The method of claim 6, comprising the steps of:
1) In an organic solvent, carrying out substitution reaction on a deuterated general formula compound dPEG-B-1 and deuterated methyl polyethylene glycol dPEG-B-2 to obtain a deuterated general formula intermediate dPEG-B-3;
2) Under the alkaline catalysis, carrying out epoxy hydrolysis reaction on the deuterated general-formula intermediate dPEG-B-3 to obtain a deuterated general-formula intermediate dPEG-B-4;
3) Under the action of a condensing agent, carrying out esterification reaction on a deuterated general formula intermediate dPEG-B-4 and a deuterated general formula compound dPEG-B-5 to obtain a deuterated general formula compound dPEG-B;
synthetic route of general formula B.
11. A combination of a compound according to any one of claims 1 to 10 and a therapeutic and/or prophylactic agent.
12. The composition of claim 11, further comprising one or more excipients selected from the group consisting of neutral lipids, steroids, and cationic lipids.
13. A composition as claimed in claim 12, wherein the neutral lipids of the component are selected from one or more of the following in admixture: 1, 2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1, 2-dimyristyl-sn-glycero-phosphocholine (DMPC), 1, 2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1, 2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and Sphingomyelin (SM).
14. The composition of claim 12, wherein the neutral lipid is DSPC.
15. A composition as claimed in any one of claims 11 to 12, wherein the steroid in the component is selected from a mixture of one or more of: cholesterol, coprosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol.
16. The composition of claim 15, wherein the steroid is cholesterol.
17. A composition as claimed in any one of claims 11 to 16 wherein the cationic lipid in the component is selected from a mixture of one or more of: 4- (N, N-dimethylamino) butanol (6Z, 9Z,28Z, 31Z) -heptatriacontan-6, 9,28, 31-tetraen-19-yl ester (DLin-MC 3-DMA), heptadecan-9-yl-8- ((2-hydroxyethyl) (6-oxo-6- ((decyloxy) hexyl) amino) octanoate (SM-102), ((4-hydroxybutyl) aza-ethyl) bis (hexane-6, 1-diyl) bis (2-hexyldecanoate) (ALC-0315), 4- (N-2- (N, N-bis (2-hydroxydodecyl) ethylamino) -1-N (2-N (2-ethylamino- (2- (N, N-bis (2-hydroxydodecyl)) -2 hydroxydodecyl) ethylamino piperazine (C12-200).
18. The composition of claim 17, wherein the cationic lipid is ((4-hydroxybutyl) aza-ethyl) bis (hexane-6, 1-diyl) bis (2-hexyldecanoate) (ALC-0315), heptadecan-9-yl-8- ((2-hydroxyethyl) (6-oxo-6- ((decyloxy) hexyl) amino) octanoate (SM-102).
19. The composition of claim 12, wherein the cationic lipid is ((4-hydroxybutyl) aza-ethyl) bis (hexane-6, 1-diyl) bis (2-hexyldecanoate) (ALC-0315) deuterated analog, deuterated analog of heptadecan-9-yl-8- ((2-hydroxyethyl) (6-oxo-6- ((decyloxy) hexyl) amino) octanoate (SM-102), as shown in structural formula C, D;
R 1 ,R 2 ,R 3 ,R4,R 5 ,R 6 ,R 7 r8 are each independently 2 "hydrogen" isotopes: including hydrogen, deuterium, embodied as a combination of "HH", "HD" and "DD";
R 1 ,R 2 ,R 3 and R4, each independently are 2 "hydrogen" isotopes: including hydrogen, deuterium, as embodied by a combination of "HH", "HD" and "DD".
21. the composition of any one of the preceding claims, wherein the therapeutic and/or prophylactic agent is a vaccine or compound capable of eliciting an immune response, including nucleic acids.
22. The composition of claim 11, wherein the nucleic acid is RNA selected from the group consisting of: siRNA, airRNA, miRNA, dsRNA, shRNA, mRNA and mixtures thereof.
23. The composition of claim 22, wherein the RNA is mRNA.
24. A method of administering a therapeutic and/or prophylactic agent to a subject in need thereof, the method comprising preparing or providing a composition according to any one of the preceding claims, and administering the composition to the subject.
25. The subject of any one of the preceding claims is a mammal or a human.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111133137.0A CN115850686A (en) | 2021-09-27 | 2021-09-27 | Novel deuterated PEG lipid compound, preparation method, composition and application thereof |
PCT/CN2022/095095 WO2023045377A1 (en) | 2021-09-27 | 2022-05-26 | Novel deuterated peg lipid compound, preparation method therefor, composition and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111133137.0A CN115850686A (en) | 2021-09-27 | 2021-09-27 | Novel deuterated PEG lipid compound, preparation method, composition and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115850686A true CN115850686A (en) | 2023-03-28 |
Family
ID=85652835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111133137.0A Pending CN115850686A (en) | 2021-09-27 | 2021-09-27 | Novel deuterated PEG lipid compound, preparation method, composition and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115850686A (en) |
WO (1) | WO2023045377A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010056344A1 (en) * | 2008-11-14 | 2010-05-20 | Concert Pharmaceuticals Inc. | Substituted dioxopiperidinyl phthalimide derivaties |
CN104415026A (en) * | 2013-08-31 | 2015-03-18 | 成都渊源生物科技有限公司 | Application of deuterated fumaric acid-enriched derivative in treatment of multiple sclerosis |
MX2020004912A (en) * | 2013-10-25 | 2021-05-21 | Insmed Inc | Prostacyclin compounds, compositions and methods of use thereof. |
CA3160511A1 (en) * | 2020-02-04 | 2021-08-12 | Susanne RAUCH | Coronavirus vaccine |
CR20220395A (en) * | 2020-02-14 | 2022-10-27 | Merck Sharp & Dome Llc | Hpv vaccine |
CN115197079A (en) * | 2021-04-08 | 2022-10-18 | 厦门赛诺邦格生物科技股份有限公司 | Polyethylene glycol lipid and liposome modified by same, pharmaceutical composition containing liposome, preparation and application of pharmaceutical composition |
-
2021
- 2021-09-27 CN CN202111133137.0A patent/CN115850686A/en active Pending
-
2022
- 2022-05-26 WO PCT/CN2022/095095 patent/WO2023045377A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023045377A1 (en) | 2023-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1019365B1 (en) | Novel compositions for the delivery of negatively charged molecules | |
US7585519B2 (en) | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | |
US6034137A (en) | Cationic lipids for gene therapy | |
WO2023186149A1 (en) | Lipid compound, composition containing same, and use thereof | |
WO2023015904A1 (en) | Novel cationic lipid compound | |
CN112472822A (en) | Construction and application of endoplasmic reticulum targeted nano drug delivery system | |
WO2023024513A1 (en) | Novel cationic lipid compound | |
WO2023029928A1 (en) | Amino lipid and application thereof | |
WO2022037465A1 (en) | Lipid nanoparticle | |
CN115745942A (en) | Novel cationic lipid compounds | |
WO2023029593A1 (en) | Novel cationic lipid compound | |
CN115850686A (en) | Novel deuterated PEG lipid compound, preparation method, composition and application thereof | |
WO2023024515A1 (en) | Novel cationic lipid compound | |
CN116574070A (en) | Multi-tail type ionizable lipid, and preparation method and application thereof | |
JP7260717B2 (en) | Lipidoids and their use for nucleic acid transfection | |
CN113214171B (en) | Amphiphilic dendrimers, synthesis and use thereof as drug delivery systems | |
CN115894281A (en) | Novel cationic lipid compounds, preparation method, composition and application thereof | |
CN115710193A (en) | Novel cationic lipid compounds | |
CN115703714A (en) | Novel cationic lipid compounds | |
WO2023024512A1 (en) | Novel cationic lipid compound | |
CN115925604A (en) | Pyrrolidine novel lipid compound, preparation method, composition and application thereof | |
WO2023035652A1 (en) | Novel cationic lipid compound | |
CN115710196A (en) | Novel cationic lipid compounds | |
CN115745941A (en) | Novel cationic lipid compounds | |
WO2023029478A1 (en) | Novel cationic lipid compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |